Pretraga

Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1162933

SGLT2 inhibitors and the risk of urinary tract infections in patients with heart failure: A pooled analysis examining safety endpoints

Borovac, Josip Anđelo; Tičinović Kurir, Tina; Mustapić, Ivona; Kumrić, Marko; Božić, Joško; Glavaš, Duška; D'Amario, Domenico
SGLT2 inhibitors and the risk of urinary tract infections in patients with heart failure: A pooled analysis examining safety endpoints // Kardiologia Polska, 80 (2022), 2; 198-201 doi:10.33963/KP.a2021.0172 (međunarodna recenzija, kratko priopcenje, znanstveni)

CROSBI ID: 1162933 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
SGLT2 inhibitors and the risk of urinary tract infections in patients with heart failure: A pooled analysis examining safety endpoints

Autori
Borovac, Josip Anđelo ; Tičinović Kurir, Tina ; Mustapić, Ivona ; Kumrić, Marko ; Božić, Joško ; Glavaš, Duška ; D'Amario, Domenico

Izvornik
Kardiologia Polska (0022-9032) 80 (2022), 2; 198-201

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, kratko priopcenje, znanstveni

Ključne riječi
SGLT2 ; sodium glucose co-transporter 2 inhibitors ; heart failure ; sotagliflozin ; empagliflozin ; dapagliflozin ; canagliflozin ; HFrEF ; HFpEF ; heart failure with reduced ejection fraction ; heart failure with preserved ejection fraction ; meta-analysis ; UTI ; urinary tract infections

Sažetak
Taken together, this work, based on high-quality randomized trial data, showed that the risk of urinary tract infections is similar among heart failure patients assigned to SGLT2 inhibitor compared to those assigned to placebo, although this might be biased by the inadequate definitions and lack of systematic registration of these events in most of the examined trials. These findings provide important safety reassurance for patients with heart failure as well as for practicing cardiologists and other prescribers of this class of drugs.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA

Ustanove:
KBC Split,
Medicinski fakultet, Split,
Sveučilište u Splitu Sveučilišni odjel zdravstvenih studija

Profili:

Avatar Url Marko Kumrić (autor)

Avatar Url Duška Glavaš (autor)

Avatar Url Josip Anđelo Borovac (autor)

Avatar Url Joško Božić (autor)

Avatar Url Tina Tičinović Kurir (autor)

Poveznice na cjeloviti tekst rada:

doi journals.viamedica.pl

Citiraj ovu publikaciju:

Borovac, Josip Anđelo; Tičinović Kurir, Tina; Mustapić, Ivona; Kumrić, Marko; Božić, Joško; Glavaš, Duška; D'Amario, Domenico
SGLT2 inhibitors and the risk of urinary tract infections in patients with heart failure: A pooled analysis examining safety endpoints // Kardiologia Polska, 80 (2022), 2; 198-201 doi:10.33963/KP.a2021.0172 (međunarodna recenzija, kratko priopcenje, znanstveni)
Borovac, J., Tičinović Kurir, T., Mustapić, I., Kumrić, M., Božić, J., Glavaš, D. & D'Amario, D. (2022) SGLT2 inhibitors and the risk of urinary tract infections in patients with heart failure: A pooled analysis examining safety endpoints. Kardiologia Polska, 80 (2), 198-201 doi:10.33963/KP.a2021.0172.
@article{article, author = {Borovac, Josip An\djelo and Ti\v{c}inovi\'{c} Kurir, Tina and Mustapi\'{c}, Ivona and Kumri\'{c}, Marko and Bo\v{z}i\'{c}, Jo\v{s}ko and Glava\v{s}, Du\v{s}ka and D'Amario, Domenico}, year = {2022}, pages = {198-201}, DOI = {10.33963/KP.a2021.0172}, keywords = {SGLT2, sodium glucose co-transporter 2 inhibitors, heart failure, sotagliflozin, empagliflozin, dapagliflozin, canagliflozin, HFrEF, HFpEF, heart failure with reduced ejection fraction, heart failure with preserved ejection fraction, meta-analysis, UTI, urinary tract infections}, journal = {Kardiologia Polska}, doi = {10.33963/KP.a2021.0172}, volume = {80}, number = {2}, issn = {0022-9032}, title = {SGLT2 inhibitors and the risk of urinary tract infections in patients with heart failure: A pooled analysis examining safety endpoints}, keyword = {SGLT2, sodium glucose co-transporter 2 inhibitors, heart failure, sotagliflozin, empagliflozin, dapagliflozin, canagliflozin, HFrEF, HFpEF, heart failure with reduced ejection fraction, heart failure with preserved ejection fraction, meta-analysis, UTI, urinary tract infections} }
@article{article, author = {Borovac, Josip An\djelo and Ti\v{c}inovi\'{c} Kurir, Tina and Mustapi\'{c}, Ivona and Kumri\'{c}, Marko and Bo\v{z}i\'{c}, Jo\v{s}ko and Glava\v{s}, Du\v{s}ka and D'Amario, Domenico}, year = {2022}, pages = {198-201}, DOI = {10.33963/KP.a2021.0172}, keywords = {SGLT2, sodium glucose co-transporter 2 inhibitors, heart failure, sotagliflozin, empagliflozin, dapagliflozin, canagliflozin, HFrEF, HFpEF, heart failure with reduced ejection fraction, heart failure with preserved ejection fraction, meta-analysis, UTI, urinary tract infections}, journal = {Kardiologia Polska}, doi = {10.33963/KP.a2021.0172}, volume = {80}, number = {2}, issn = {0022-9032}, title = {SGLT2 inhibitors and the risk of urinary tract infections in patients with heart failure: A pooled analysis examining safety endpoints}, keyword = {SGLT2, sodium glucose co-transporter 2 inhibitors, heart failure, sotagliflozin, empagliflozin, dapagliflozin, canagliflozin, HFrEF, HFpEF, heart failure with reduced ejection fraction, heart failure with preserved ejection fraction, meta-analysis, UTI, urinary tract infections} }

Časopis indeksira:


  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE

Citati:

    Altmetrijski pokazatelji:


    Podijeli:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font
    CROSBI koristi kolačiće (cookies) kako bi poboljšao funkcionalnost stranice.